Mesa Laboratories will release its Q4 and fiscal year 2026 financial results on May 27, 2026.
Quiver AI Summary
Mesa Laboratories, Inc. announced that it will release its financial results for the fourth quarter and the fiscal year ending March 31, 2026, on May 27, 2026, at 6:00 A.M. Eastern Time. The company is a leader in developing life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device sectors. These offerings aim to enhance product integrity, safety for patients and workers, and overall quality of life. Contact information for company executives is provided, and further details can be found on their website.
Potential Positives
- Mesa Laboratories is set to announce its financial results, indicating a commitment to transparency and communication with stakeholders.
- The press release highlights Mesa's position as a global leader in life science tools and critical quality control solutions, reinforcing its credibility in the industry.
- By focusing on regulated applications in pharmaceuticals and healthcare, the company showcases its relevance and importance in essential sectors.
- The announcement of financial results can drive investor interest and potentially impact stock performance positively.
Potential Negatives
- The press release does not provide any specific financial results or data, which may signal a lack of confidence in the company's performance.
- There is a long gap until the actual announcement of financial results, which may lead to speculation or concern regarding the company's financial health.
FAQ
When will Mesa Laboratories release its financial results?
Mesa Laboratories will release its financial results on May 27, 2026, at 6:00 A.M. ET.
What fiscal period do the results cover?
The results cover the fourth quarter and the fiscal year ended March 31, 2026.
What industry does Mesa Laboratories operate in?
Mesa Laboratories operates in the life sciences, pharmaceutical, healthcare, and medical device industries.
How can I learn more about Mesa Laboratories?
You can learn more about Mesa Laboratories by visiting their website at www.mesalabs.com.
Who are the key contacts for Mesa Laboratories?
The key contacts include Siddhartha Kadia, President and CEO, and John Sakys, Vice President and CFO.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MLAB Insider Trading Activity
$MLAB insiders have traded $MLAB stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MLAB stock by insiders over the last 6 months:
- SHIRAZ SHABANALI LADIWALA purchased 3,500 shares for an estimated $252,805
- R TONY TRIPENY purchased 1,315 shares for an estimated $99,940
- MARK CHRISTOPHER CAPONE purchased 1,301 shares for an estimated $99,331
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$MLAB Revenue
$MLAB had revenues of $65.1M in Q3 2026. This is an increase of 3.64% from the same period in the prior year.
You can track MLAB financials on Quiver Quantitative's MLAB stock page.
$MLAB Hedge Fund Activity
We have seen 95 institutional investors add shares of $MLAB stock to their portfolio, and 56 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CONESTOGA CAPITAL ADVISORS, LLC removed 426,457 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $33,476,874
- LONG PATH PARTNERS LP added 227,223 shares (+inf%) to their portfolio in Q4 2025, for an estimated $17,837,005
- SIMCOE CAPITAL MANAGEMENT, LLC removed 190,929 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $14,987,926
- GLENMEDE TRUST CO NA removed 146,544 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $11,503,704
- MILLENNIUM MANAGEMENT LLC removed 129,352 shares (-96.7%) from their portfolio in Q4 2025, for an estimated $10,154,132
- BOSTON PARTNERS added 99,019 shares (+86.6%) to their portfolio in Q4 2025, for an estimated $7,772,991
- SELECT EQUITY GROUP, L.P. added 79,720 shares (+62.9%) to their portfolio in Q4 2025, for an estimated $6,258,020
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Full Release
LAKEWOOD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ended March 31, 2026 at approximately 6:00 A.M. Eastern Time (ET) on Wednesday, May 27, 2026.
About Mesa Laboratories
Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
Mesa Laboratories Contacts
Siddhartha Kadia, President and CEO
John Sakys, Vice President and CFO
1-303-987-8000
For more information about Mesa Laboratories, please visit our website at www.mesalabs.com .
